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Abstract
Background: Clotrimazole is an azole derivative with promising anti-cancer effects. This drug interferes with the activity of
glycolytic enzymes altering their cellular distribution and inhibiting their activities. The aim of the present study was to
analyze the effects of clotrimazole on the growth pattern of breast cancer cells correlating with their metabolic profiles.
Methodology/Principal Findings: Three cell lines derived from human breast tissue (MCF10A, MCF-7 and MDA-MB-231)
that present increasingly aggressive profiles were used. Clotrimazole induces a dose-dependent decrease in glucose uptake
in all three cell lines, with Ki values of 114.3611.7, 77.167.8 and 37.864.2 mM for MCF10A, MCF-7 and MDA-MB-231,
respectively. Furthermore, the drug also decreases intracellular ATP content and inhibits the major glycolytic enzymes,
hexokinase, phosphofructokinase-1 and pyruvate kinase, especially in the highly metastatic cell line, MDA-MB-231. In this
last cell lineage, clotrimazole attenuates the robust migratory response, an effect that is progressively attenuated in MCF-7
and MCF10A, respectively. Moreover, clotrimazole reduces the viability of breast cancer cells, which is more pronounced on
MDA-MB-231.
Conclusions/Significance: Clotrimazole presents deleterious effects on two human breast cancer cell lines metabolism,
growth and migration, where the most aggressive cell line is more affected by the drug. Moreover, clotrimazole presents
little or no effect on a non-tumor human breast cell line. These results suggest, at least for these three cell lines studied, that
the more aggressive the cell is the more effective clotrimazole is.
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Introduction
Among the physiological hallmarks of cancer, altered glucose
metabolism is perhaps the most common. The Warburg effect has
been observed in approximately 90% of human tumors and the
biochemical origins of this phenomenon have been extensively
studied [1–4]. Aerobic glycolysis may be required for new biomass
formation [5]. In fact, proliferation of cancer cells is accompanied
by activation of glycolysis [6], which occurs even at normal oxygen
concentrations. Moreover, glycolysis may confer tumor cells with
the ability to adapt to new microenvironments or cope with stress
during tumor progression and metastasis [7].
Observations suggest that blocking glycolysis might diminish
tumor progression and enhance the efficacy of chemo- and
radiotherapy. However, inhibition of glycolytic enzymes is
expected to have secondary effects on cell physiology, due to the
additional functions of these proteins. Clotrimazole, an antifungal
drug, has been successfully used to diminish the size and
development of intracranial gliomas (C6 and 9L), prolonging
survival in rodents [8]. Moreover, the drug also affects glycolytic
enzymes decreasing hexokinase (HK) binding to the outer
mitochondrial membrane [9] and detaching phosphofructoki-
nase-1 (PFK-1) and aldolase from the cytoskeleton [10–12].
Indeed, clotrimazole is able to trigger apoptosis, which is directly
correlated with its ability to displace HK from mitochondria [9]
and PFK-1 and aldolase from the cytoskeleton [12]. The location
of these glycolytic enzymes within the intracellular milieu is an
important feature of glycolysis regulation [13] and thus, altering
the intracellular distribution of these enzymes, clotrimazole is
probably affecting the glycolytic flux.
The aim of this study was to analyze the effects of the
clotrimazole on viability, growth, mobility and glycolytic profile
of three human breast cell lines: MCF10A, MCF-7 and MDA-
MB-231. The MCF10A human mammary epithelial cell is a
normal strain, while MCF-7 and MDA-MB-231 cells are human
breast-derived cell lines with tumorigenic and metastatic
profiles, respectively. Here we present evidences that clotrima-
zole presents more pronounced effects on the tumorigenic and
metastatic cells, while presenting minimal effects over the non-
t u m o r a lc e l ls t r a i n .
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Clotrimazole inhibits the migratory phenotype in breast
cancer cells
To assess the effects of clotrimazole on the growth profiles of
breast cell lines, cellular migration and proliferation were
evaluated. The migration potential of MCF10A, MCF-7 and
MDA-MB-231 cells was initially assessed using the Transwell assay
(Fig. 1A). Our results confirm that there is a significant difference
between the migration potential of these cells, which increases with
the aggressiveness of the cell (MCF10A,MCF-7,MDA-MB-
231). The presence of 50 mM clotrimazole inhibits migration of
MCF-7 and MDA-MB-231 cells, but has no effect on MCF10A
cells. Proportionally, the effects of clotrimazole were more
pronounced on MDA-MB-231 migration (5966% inhibition)
than on MCF-7 (3265% inhibition). Moreover, using the scratch
assay, we compared cell mobility in the presence or absence of
50 mM clotrimazole (Fig. 1B and 1C). In accordance with the
previous results, there is a significant difference between the
migration rates of the cell lines assessed through this later
technique. The evaluated migration increased approximately
1.5-fold and 2- to 3-fold for MCF-7 and MDA-MB-231 cells,
respectively, when compared with control cells (black bars,
Fig. 1B). Within 12 hours, the migration rate of the tumorigenic
cells was significantly reduced by clotrimazole (grey bars, Fig. 1B).
Clotrimazole inhibited mobility of MDA-MB-231 cells by
3664%, of MCF-7 cells by 1663%, but was unable to affect
the MCF10A migration rate (Fig. 1B and 1C). These results
suggest that clotrimazole prevents cell migration, which may
contribute to the anti-metastatic potential of the drug.
To clarify that these results were not due to the effect of
clotrimazole on the cell proliferation, we determined the incorpo-
ration of BrdU into DNA of synchronized proliferating breast cell
lines in the absence or presence of different concentration of
clotrimazole. Fig. 2A shows cell proliferation in the absence of
clotrimazoleafter24 h ofBrdUincubation.MCF-7and MDA-MB-
231 cells display a 10- and 20-fold higher proliferation rate,
respectively, when compared with the MCF10A cells. Treatment
with clotrimazole (0–100 mM) inhibited the cell proliferation in all
cell lines (Fig. 2B). Twenty-four hours after cell cycle reentry, which
is initiated by adding fresh culture medium containing fetal serum,
the percentage of proliferating cells was significantly decreased by
clotrimazole.Surprisingly,25 mMclotrimazolecompletelyinhibited
MCF10A proliferation (98613% inhibition). However, this same
concentration had no effect on tumoral cell lines. MCF-7 cells
displayed a linear response to increasing clotrimazole concentra-
tions, reaching 70% inhibition at 100 mM. Furthermore, clotrima-
zole also inhibited proliferation of MDA-MB-231 cells, but the
maximum inhibition (50%) occurred at 50 mM and persisted even
at the highest concentration tested (100 mM).
Clotrimazole diminishes glucose uptake and intracellular
ATP
Proliferation in cancer cells is accompanied by activation of
glycolysis [6], which occurs even in the presence of a normal
oxygen concentration. This preferential use of glycolysis by cancer
cells under aerobic conditions is known as the Warburg effect [14]
and is characterized by high glycolytic rates in cancer cells with
high rates of lactate production per glucose consumed. Our
previous results have shown that breast cancer cells present a
distinct glycolytic rate; the metastatic cell line (MDA-MB-231)
showed lower consumption of glucose and higher production of
lactate when compared to a non-tumorigenic cell line (MCF10A).
Moreover, MCF-7 cells, which are tumorigenic and non-
metastatic, presented an intermediate glycolytic rate [15]. In
order to evaluate the metabolic profiles of these breast cell lines
after treatment with clotrimazole, we incubated the cells in 96 well
plates with different concentrations of clotrimazole (0–100 mM) for
24 h. Clotrimazole reduces glucose uptake by the cells in a dose-
dependent fashion (Fig. 3A). The inhibition constant (Ki) for
glucose uptake inhibition by clotrimazole was calculated and
found to be 114.3611.7, 77.167.8 and 37.864.2 mM for
MCF10A, MCF-7 and MDA-MB-231 cells, respectively (Fig. 3B).
These results clearly demonstrate that clotrimazole has more
pronounced effects on cells with the highest glycolytic rates and
Warburg effect.
We also analyzed the mitochondrial reduction activity and the
cellular ATP levels after the treatment with clotrimazole. Fig. 3C
shows a dose-dependent reduction of the mitochondrial activity in
these cells, with the maximum inhibition being approximately
60% for MDA-MB-231 cells treated with 100 mM clotrimazole. At
that concentration, both MCF10A and MCF-7 cell lines
demonstrate 40% lower mitochondrial activity than corresponding
cells treated with 50 mM clotrimazole. Once more, the drug was
more effective in the metastatic cell line than the non-tumoral cells
in the same condition (Fig. 3C). Furthermore, we evaluated the
effects of clotrimazole on the cellular ATP levels. Clotrimazole
reduces the cellular ATP of tumorigenic cells in a dose-dependent
manner (Fig. 3D). Interestingly, MCF10A cells are completely
resistant to the presence of the drug. In fact, we observed 26% and
35% higher ATP content after the treatment with 50 and 75 mM
clotrimazole, respectively. However, MCF-7 and MDA-MB-231
cells display a progressive dose-dependent inhibition curve
reaching 95% reduction of the ATP content with 75 mM
clotrimazole.
Glycolytic enzymes from tumorigenic cells are selectively
inhibited by clotrimazole
The results above show that clotrimazole alters the rates of
glucose uptake, mitochondrial activity and generation of ATP in
the cell lines, with more pronounced effects on the cancerous cell
lines than non-tumorigenic cells. Additionally, these effects
probably are not due to a specific action of clotrimazole on
mitochondrial activity because all the cell lines, regardless of their
phenotype, are not responsive to clotrimazole up to 100 mM
(Fig. 3C). Therefore, our next objective was to investigate whether
the antineoplasic effects of clotrimazole occurs by its direct action
on glycolysis. Therefore, we evaluated the effects of the drug on
the three enzymes that regulate the glycolytic flux: hexokinase
(HK), phosphofructokinase-1 (PFK-1) and pyruvate kinase (PK).
We evaluated HK activity in all breast cells using a 24 h
incubation time with different concentrations of clotrimazole.
Fig. 4A shows HK dose-dependent inhibition curves for MCF10A,
MCF-7 and MDA-MB-231 cells, where clotrimazole has a more
pronounced effect in tumoral cell lines compared to the non-
tumoral cells. HK activity in MCF10A cells was inhibited by only
46% by clotrimazole, whereas, at the same concentration (100 mM
clotrimazole), HK activity in MCF-7 and MDA-MB-231 cells was
inhibited by 90% and 96%, respectively. To align our results with
the data in the literature, we used the 3-bromopyruvate (3-BrPA),
a well-known inhibitor of energy metabolism, which has been
proposed as a specific anticancer agent due to its high tumor
selectivity [16,17]. Surprisingly, 3-BrPA has different effects on
these cell lines, showing a more pronounced inhibition of HK in
the MCF10A cells (Table 1). This is an interesting result because,
until now, both drugs (3-BrPA and clotrimazole) were thought to
have the same mechanism of action in cancer cells: through the
detachment of the mitochondria-associated HKII. Although this is
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suggest an additional mechanism of cell death induced by the
direct inhibition of HK by clotrimazole (Fig. 4A, inset).
Meira and co-workers showed that clotrimazole inhibits
phosphofructokinase-1 in MCF-7 cells [12]. To investigate this
inhibition further, we analyzed the effects of clotrimazole on breast
cell lines. Similar to what was observed for HK, clotrimazole
inhibits PFK-1 activity in a dose-dependent manner (Fig. 4B). The
effects of clotrimazole are dependent on the tumorigenic
phenotype of the cell, as MCF10A cells are more resistant to the
inhibition than MCF-7 and MDA-MB-231 cells. Once again, we
observed 90–95% inhibition in tumorigenic cells and a less
dramatic effect of clotrimazole on MCF10A cells.
We also evaluated the effects of clotrimazole on the last enzyme
of glycolysis, pyruvate kinase (PK). Once more, clotrimazole
progressively inhibited enzyme activity, with a substantial effect on
MCF-7 and MDA-MB-231 cells (Fig. 4C). However, there was a
more significant inhibition of PK in MCF10A cells when
compared with the results for HK and PFK in this cell line. This
result may be due to the effects of clotrimazole on previous steps of
glycolysis or on glucose uptake in these cells.
After entering the cell, glucose is converted by HK to glucose 6-
phosphate, which can be shunted to the pentose phosphate
pathway (PPP). The increase in the PPP flux is directly associated
with inhibition of the apoptosis. This is due to an increased
generation of NADPH and, therefore, reduced glutathione, which
also promotes the removal of reactive oxygen species (ROS) in
cells [18]. To investigate the diversion of glucose 6-phosphate from
glycolysis to PPP, we verified the activity of glucose 6-phosphate
dehydrogenase (G6PDH), which is the enzyme responsible for the
first irreversible reaction of the PPP. Similar to the results observed
for the glycolytic enzymes, clotrimazole inhibits the PPP (Fig. 4D).
The inhibitory effect of clotrimazole is more pronounced in MCF-
7 and MDA-MB-231 cells than in MCF10A cells. The complete
inhibition of PPP was obtained with 75 mM clotrimazole for
tumorigenic cell lines and 100 mM clotrimazole for the MCF10A
cells.
Metabolic effects of clotrimazole induce the loss of
viability
Finally, we investigated the consequences of the metabolism
inhibition induced by clotrimazole on cell viability. Published data
have shown that clotrimazole reduces the viability of MCF-7 cells,
CT-26 colon adenocarcinoma cells and Lewis lung carcinoma
[11,19], as well as B16 melanoma cells [10,20]. However, as most
of our results demonstrate a cellular phenotype-dependent effect of
clotrimazole, our objective was to evaluate whether cell viability
also responds in a similar way. The cell viability was evaluated by
the activity of lactate dehydrogenase (LDH) leaked to the medium
and permeability of the cells to trypan blue dye. As shown in
Fig. 5A, clotrimazole is does not affect the leakage of LDH of
MCF10A cells in any of the concentrations tested, even at 100 mM
clotrimazole (data not shown), as compared to untreated controls.
This result strongly suggests that the drug does not affect MCF-
10A cells integrity. This picture changes when we analyze the
effects of clotrimazole on LDH leakage from MCF-7 cells.
Although 50 mM clotrimazole does not alter LDH leakage from
these cells, 75 mM clotrimazole promotes a significant increase of
Figure 1. Clotrimazole inhibits the migration of breast cell lines. (A) The migration of MCF10A, MCF-7 and MDA-MB-231 cells was assessed by
transwell assays after 24 h incubation in the absence or presence of 50 mM clotrimazole; (B) Cell migration rate was calculated from scratch assays.
The images were analyzed and data were expressed in mm6h
21. (C) Scratch migration assay for control and 50 mM clotrimazole-treated cells. The
filling of scratchs by migrated cells at time 0, 6 and 12 h was imaged. MCF-7 and MDA-MB-231 cells have a more motile appearance and migrate
faster than MCF10A. Bars are mean 6 SEM of three independent experiments. * P,0.05 compared with control condition in the absence of the drug;
# P,0.05 compared with MCF10A cells.
doi:10.1371/journal.pone.0030462.g001
Figure 2. Clotrimazole decreases cell proliferation of MCF10A, MCF-7 and MDA-MB-231 cells. (A) Basal cell proliferation of human breast
cell lines was analyzed using the BrdU incorporation assay. The graph shows the europium-based TRF cell proliferation assay. * P,0.05, in comparison
with MCF10A cell line. (B) Effects of clotrimazole on cell proliferation after 24 h treatment using BrdU incorporation assay. Values are mean 6
standard error (SE) of four different experiments.
# P,0.05, in comparison with the control; * P,0.05, comparing 50, 75 and 100 mM clotrimazole with
the control in the absence of the drug for both cell lines (MCF-7 and MDA-MB-231).
doi:10.1371/journal.pone.0030462.g002
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On the other hand, MDA-MB-231 cells viability is more
susceptible to clotrimazole effects, since this cell line presents
increased LDH leakage upon the treatment with 50 mM
clotrimazole for 24 hours. Moreover, treatment of MDA-MB-
231 cell with 75 mM clotrimazole increases 3.5 times the leaked
LDH suggesting that the viability of these cells is severely
compromised upon this treatment. These data are confirmed
analyzing the exclusion of trypan blue dye by the different cell
lines treated with clotrimazole (Fig. 5B). These results corroborate
that MCF10A cells integrity is not affected up to 100 mM
clotrimazole. Moreover, it is clear now that upon the treatment
with clotrimazole the viability of MCF-7 and MDA-MB-231 cells
decrease in a dose-responsive mode. Furthermore, MDA-MB-231
cells are more sensitive to 50 mM clotrimazole and higher
concentrations, as compared to MCF-7 cells. Altogether, these
data reinforce the preferential action of clotrimazole over the
tumorigenic cell lines among those tested here, with an even more
preferential effect over the most aggressive cell line.
Discussion
The use of metabolic pathways as useful molecular targets in
tumors prompted us to investigate the effects of drugs that affect
cell metabolism, especially glycolysis. In this paper, we report the
metabolic and anti-metastatic effects of the imidazole derivative
clotrimazole in breast cell lines. Our data reveal that clotrimazole
has more pronounced effects on tumorigenic cell lines that present
the Warburg effect [15]. There are, at least, three major possible
explanations to the preferential effects of clotrimazole on
Figure 3. Effects of clotrimazole on glucose uptake, mitochondrial reduction activity and cellular ATP content in breast cell lines. (A)
Comparison of glucose uptake in MCF10A, MCF-7 and MDA-MB-231 cells. Glucose uptake was determined after 15, 30 and 45 min incubation
through cells incubation with 5 mM 6-NBDG, a fluorescent glucose analogue. The results obtained are plotted as percentage of control in a function
of clotrimazole concentration. (B) Glucose uptake experimental data was fitted in an equation as described in Methods and the Ki values were
plotted. Bars are mean 6 SEM of three independent experiments. * P,0.05, comparing with MCF10A cells. (C) Percent of mitochondrial reduction
activity, evaluated by MTT assay. All values were normalized to that of control condition in the absence of the drug. (D) Intracellular ATP content
measured by relative firefly luciferase activity (PerkinElmer ATPLite Kit). Error bars represent standard errors from five independent experiments.
*P ,0.05 compared to control for MCF10A cells.
# P,0.05, compared to control for MCF-7 and MDA-MB-231 cell lines.
doi:10.1371/journal.pone.0030462.g003
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more readily and in an aggressiveness-dependent pattern, (2)
glycolytic enzymes in cancerous cells are more sensitive to the
effects of clotrimazole what could be due to an isoform expression
specificity, and (3) cancerous cells rely on glycolysis more heavily
and are therefore more sensitive, which is strongly supported by
the Warburg effect observed in tumoral and not in non-tumoral
cells. The first possibility is reasonably plausible, but we have not
evaluated it and therefore we cannot discuss it. The other two
possibilities seem to be supported by our results, although we
cannot unambiguously discriminate between them.
In non-tumoral cells, at least 90% of ATP production is
provided by mitochondrial oxidative phosphorylation, while in
tumor cells, approximately 50% is dependent on cytoplasmic,
Figure 4. Glycolytic enzymes activity and G6PDH activity are inhibited by clotrimazole. Cell lines were grown to confluence in the
indicated media as described in Methods. Cell lysates were used to evaluate HK, PFK-1, PK and G6PDH activities (panel A, B, C and D respectively) as
described in Methods. Plotted values are mean 6 standard errors of five independent experiments. (A)
# P,0.05 compared to control in the absence
of clotrimazole; * P,0.05, compared to control in the absence of clotrimazole. (B)
# P,0.05 compared to control in the absence of clotrimazole;
*P ,0.05, compared to control and to MCF10A in the presence of clotrimazole. (C) The differences among the results obtained with the distinct
clotrimazole concentrations tested are statistically significant. * indicate differences between MCF10A and tumoral breast cell lines. (D)
# P,0.05
compared to control in the absence of clotrimazole; * P,0.05, compared to control and to MCF10A in the presence of clotrimazole.
doi:10.1371/journal.pone.0030462.g004
Table 1. 3-BrPA effects on HK activity from breast cell lines.
Cell line
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inhibits glucose uptake (Fig. 3A) and mitochondrial activity
(Fig. 3C) more efficiently in the tumorigenic cell lines. These
effects result in alterations in ATP content that are also more
pronounced in the tumorigenic cell lines. However, it seems that
this later effect is more related to the inhibition of glycolysis, since
mitochondrial activity is not reduced by 50 mM clotrimazole,
while glucose consumption and ATP content are affected by even
lower concentrations of the drug. These data highlight the
importance of aerobic glycolysis for energy production in
tumorigenic cells. The increased content of ATP measured in
MCF-10A cell upon clotrimazole treatment might be the result of
clotrimazole effects on this cell metabolism and proliferation.
Comparing clotrimazole effects on cells proliferation and metab-
olism one can observe that the drug blocks the proliferation of
MCF-10A cells (Fig. 2B), decreases its glucose consumption
(Fig. 3A) and do not affect its mitochondrial activity (Fig. 3C).
Similar results are observed for the tumorigenic cell lines but with
lesser extent on proliferation and greater extent on metabolism.
Since proliferation if the highest ATP-consuming cellular process,
the resultant ATP content of MCF-10A cells increases upon
clotrimazole treatment.
It is important to mention that the lack of clotrimazole effects on
MCF10A cell line cannot be attributed to fact that this cell line is
grown in a different medium (DMEM/F12 with 5% FHS, instead
of DMEM with 10% FBS used for MCF-7 and MDA-MB-231).
We have performed control experiments assaying the effects of
clotrimazole on cell viability and enzymes activity of MCF-10A
cells grown in DMEM/F12 but incubated with DMEM for
24 hours during the clotrimazole treatment and the results were
not different from those presented here. We decided to perform all
the experiments using DMEM/F12 for the MCF10A cell to assure
that all the cells would be at optimal growing conditions (MCF-
10A does not grow well in DMEM with 10% FBS).
Many human tumors display a high rate of aerobic glycolysis, de
novo fatty acid synthesis, and nucleotide biosynthesis [23,24].
Previous findings suggest that the increased glucose metabolism
promotes lipogenesis and nucleotide biosynthesis, and enhances
tumor cell growth and proliferation by providing essential
synthetic and bioenergetic requirements [25–29]. Although the
metabolic alterations might not be initiating events in oncogenesis,
recent success in blocking carcinogenesis by targeting tumor
metabolism suggests that aerobic glycolysis plays an important role
in sustaining tumor growth [27–33].
After 24 hours of incubation, clotrimazole promote a pheno-
type-dependent inhibition of the key glycolytic enzymes: HK,
PFK-1 and PK. The results always present the same pattern:
MCF10A cells are less responsive to clotrimazole, whereas MCF-7
and MDA-MB-231 are sensitive to the increasing concentration of
the drug (Fig. 4). More importantly, the metastatic cell line
presents the highest clotrimazole-induced inhibition of glycolysis.
These observations are accompanied by the dose-dependent
inhibition of G6PDH, the enzyme responsible for the first
irreversible reaction of the PPP (Fig. 4D). We have not observed
differences between the effects of clotrimazole on enzymes activity
of MCF-7 and MDA-MB-231 cell lines. The drug appears to be
more effective inhibiting tumoral than non-tumoral enzymes,
without distinction on the aggressiveness of the tumoral cell line.
However, this can be an underestimated result, since here we
measured the whole enzyme activity. These measurements were
achieved under optimal substrate concentration and other reaction
conditions, which can mask some fine regulatory properties of
these enzymes, such as their association with cellular macromo-
lecular structures, described as important to cancer increased
glycolytic rates [34]. However, in order to assess these possibilities,
a profound study of the effects of clotrimazole on glycolytic
enzyme kinetics and cellular distribution should be performed,
which was not the objective of the current work.
Although cancer cells are capable of carrying out oxidative
phosphorylation, they undergo the glycolytic shift because aerobic
glycolysis is advantageous for cell proliferation and tumorigenicity
[35]. The metabolism of cancer cells, and indeed all proliferating
cells, is adapted to facilitate the uptake and incorporation of
nutrients into the biomass needed to produce a new cell.
Supporting this idea are recent studies showing that (i) several
signaling pathways implicated in cell proliferation also regulate
Figure 5. Cellular viability decreases in breast cancer cells treated with clotrimazole. Data are presented as mean 6 SE of at least five
experiments. Panel A: lactate dehydrogenase (LDH) leaked to culture medium by clotrimazole-induced cellular lyse was evaluated as described in
Methods. * P,0.05 compared to MCF10A cells in the same clotrimazole concentration. Panel B: the percentages of cells that exclude trypan blue dye
were evaluated counting the total cells and those that were intracellularly stained with the dye. Cells were counted using a TC10 Automated Cell
Counter (Bio-Rad Laboratories, CA, USA). * P,0.05 compared to MCF10A in the same clotrimazole concentration. # P,0.05 compared to MCF-7 in
the same clotrimazole concentration.
doi:10.1371/journal.pone.0030462.g005
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that (ii) certain cancer-associated mutations enable cancer cells to
acquire and metabolize nutrients in a manner conducive to
proliferation rather than efficient ATP production [5]. Moreover,
in metastases, the glycolytic phenotype persists due to increased
production of glucose-derived acid, which potentiates invasiveness
of cells into the extracellular matrix of the host tissue [36].
Our results here demonstrated that clotrimazole was able to
decrease cancer cells proliferation and viability, with minimal
effects on non-tumoral cells. Clotrimazole has been implicated in
other mechanisms affecting tumor cells migration and invasion,
such as the inhibition of the Ca
2+-activated potassium channels
[37,38] and inhibition of the enzymes of the cytochrome P450
family [39]. This latter effect of clotrimazole is critically
important and represents a reason for why clotrimazole is
practically not used for systemic treatments due to its impact on
liver CYP450 metabolism. However, clotrimazole have been used
to design more selective and less toxic compounds, such as
TRAM-34 [40], which, in addition to clotrimazole, was recently
demonstrated to inhibit glioblastoma proliferation [41]. An
interesting observation is that the effects of clotrimazole and its
analogue TRAM-34, originally designed as a specific Ca
2+-
activated potassium channels blocker, on glioblastoma prolifer-
ation are not due to any effects on this ion channel. It is not
difficult to imagine that the effects of these drugs might be related
to inhibition of glioblastoma metabolism, such as described here.
Interestingly, intracranial administration of clotrimazole has been
used to prolong the survival of rats with glioma, but no
mechanisms have been reported for this effect [8]. Clotrimazole
has been shown to induce the nuclear condensation and f-actin
depolymerization in MCF-7 cells [12] suggesting that clotrima-
zole-treated cells undergo apoptosis. In fact, decrease in glycolytic
flux has been associated elsewhere to some apoptotic events
[42,43]. In addition, studies on cell metabolism during apoptosis
in murine interleukin-3-dependent cell line revealed that the
activation of glycolytic flux is related to cell survival [42].
However, we didn’t yet explore the death mechanisms involved
in the decrease of cellular viability in response to clotrimazole on
tumor cells.
Our current results add to the growing evidence that aerobic
glycolysis contributes to cancer cell proliferation and tumorige-
nicity. Although the systemic therapeutic use of clotrimazole is
strongly limited due to its toxic effects, the present findings point to
the development of novel treatment approaches that selectively
targets glycolysis in tumor cells. These novel approaches may
identify treatments that would be more selective to aggressive
tumors with minimal effects over non-tumoral cells.
Materials and Methods
Cell lines and Materials
The human breast cancer cell line MCF-7 was obtained from
the Cell Bank of Hospital Universita ´rio Clementino Fraga Filho,
UFRJ, Brazil. MDA-MB-231 and the non-tumorigenic epithelial
MCF10A cell line were kindly supplied by Prof. Dr. Mitzi Brentani
from University of Sa ˜o Paulo, USP, Brazil. The tumor cell lines
were maintained in DMEM (Dulbecco’s modified Eagle’s
medium; Invitrogen) supplemented with 10% (v/v) FBS (fetal
bovine serum; Invitrogen) and L-glutamine. The MCF10A cell
line was maintained in DMEM/F12 medium (Invitrogen)
supplemented with 5% FHS (fetal horse serum; Gibco) plus
0.02 mg/ml EGF, 5 mg/ml insulin, 1.25 mg/ml hydrocortisone
and 0.1 mg/ml cholera toxin (Sigma Chemical, St. Louis, MO,
USA). Cells were grown at 37uCi n5 %C O 2 atmosphere.
Clotrimazole, 3-bromopyruvate, NAD
+, NADH, ATP, hexoki-
nase, glucose 6-phosphate dehydrogenase, fructose 6-phosphate,
aldolase, lactate dehydrogenase, phosphoenolpyruvate, NADP
+
and glucose 6-phosphate were obtained from Sigma. Other
reagents were of the highest purity available.
Cell viability assay, glucose uptake, mitochondrial activity
and ATP quantitative evaluation
To measure metabolic rates, cells were seeded in 96-well plates
in the appropriate medium and grown to confluence. Then, the
medium was removed, fresh medium was added, and the cells
were returned to the incubator in the presence of different
concentrations of clotrimazole (0–100 mM). After 24 h, the
medium was removed and the amount of leaked lactate
dehydrogenase (LDH) was evaluated, while mitochondrial activity
and trypan blue dye exclusion was determined in the remaining
cells using an MTT assay [44,45] and counting the cells that
exclude trypan blue [46], respectively.
Glucose uptake was determined by incubating cells with fresh
medium containing 5 mM 6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-
yl)amino)-6-deoxyglucose (6-NBDG, Molecular Probes, Invitro-
gen, Life Technologies, Carisbad, CA, USA), a fluorescent glucose
analogue. After 15, 30 and 45 min incubation, the medium was
removed, the cells were washed with 6-NBDG-free medium, and
6-NBDG taken up by the cells was evaluated by fluorescence
emission, according to the manufacturer’s instructions. The
glucose uptake rate was calculated by the linear regression of the
increase in fluorescence incorporated by the cells, and these results
are plotted as a percentage of control in a function of clotrimazole
concentration. The parameters of the following equation were
fitted to the experimental data in order to evaluate the
effectiveness of clotrimazole effects by means of the concentration




Kiz CTZ ½ 
ð1Þ
where Gin is the percentage of glucose taken up by the cells at a
given concentration of clotrimazole ([CTZ]) and Ki is the
inhibitory constant, equivalent to the concentration of clotrima-
zole promoting 50% of the maximal inhibition.
LDH activity was determined spectrophotometrically by
monitoring the conversion of NAD
+ to NADH in a lactate-
utilizing reaction [47]. Cellular ATP was assessed using a system
based on firefly (Photinus pyralis) luciferase (PerkinElmer AT-
PLite) using a VICTOR3 multilabel reader (PerkinElmer).
Spectrophotometric assay for enzymes activity
Cells were seeded in 24-well plates and grown to confluence. Then,
medium was removed and fresh medium was added, and cells were
returned to the incubator in the presence of different concentrations
of clotrimazole (0–100 mM) for 24 h. After this incubation, cells were
removed from the plates by trypsinization and counted using a
hemocytometer. Protein concentrations of cell lysates were measured
[48], and the glycolytic enzyme activities were evaluated.
Phosphofructokinase-1 (PFK-1) activity was assayed using an
enzyme-coupled method, where the oxidation of NADH was
monitored spectrophotometrically [49]. The basic medium
contain 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 1 mM fructose
6-phosphate, 1 mM ATP, 0.2 mM NADH, 2 U/ml aldolase,
4 U/ml triosephosphate isomerase and 2 U/ml a-glycerophos-
phate dehydrogenase.
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containing 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2,1 m M
glucose, 1 mM ATP, 0.2 mM NAD
+ and 1 U/ml glucose 6-
phosphate dehydrogenase as described previously [50].
Pyruvate kinase (PK) activity was measured in a medium
containing 50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 120 mM
KCl, 1 mM phosphoenolpyruvate, 1 mM ADP, 0.2 mM NADH
and 20 U/ml lactate dehydrogenase as described previously [50].
Glucose-6-phosphate dehydrogenase (G6PDH) activity was
assayed as previously described [51]. The basic medium contains
50 mM Tris-HCl (pH 7.4), 5 mM MgCl2, 0.5 mM glucose 6-
phosphate and 0.2 mM NADP
+.
For all enzymatic analyses, NADH oxidation or NAD(P)
+
reduction was determined by measuring the absorbance at
340 nm in a microplate reader (VICTOR 3, PerkinElmer).
Reactions were initiated by the addition of an aliquot of cellular
homogenate and followed online during the first-order kinetics
period. Enzymes rates was determined calculating the first
derivative of these curves. Blanks containing none of the coupled
enzymes (or without glucose 6-phosphate in the case of G‘PDH)
were performed to control for non-specific oxidation/reduction.
Each curve was performed in quadruplicate.
Cell migration assays
Cell migration was determined by using the 24-well Millicell
Hanging Cell Culture Insert (Millipore) chamber with 8 mm pore
polyethylene terephthalate (PET) membranes. The chambers were
rehydrated in serum-free medium. Complete medium with 10%
FBS or FHS was used as a chemoattractant. Suspension of 5610
4
cells/ml in serum-free medium was added to the inserts and
incubated for 24 h in the presence or absence of 50 mM
clotrimazole. Cells remaining on the upper membrane surface of
the inserts were removed with a cotton swab whereas the cells on
the lower surface were trypsinized and counted.
Cell migration was also assessed in scratch assays [52]. Briefly,
confluent MCF10A, MCF-7 and MDA-MB-231 cells plated on
tissue culture dishes were manually scratched with a 200 ml pipette
tip, washed with PBS and incubated at 37uC in complete media in
the presence or absence of 50 mM clotrimazole. At the indicated
time points, phase contrast images at specific scratch sites were
captured as previously described [53]. The images were analyzed




Cells were seeded in 96-well culture plates and grown until
confluence was reached. After 72 h serum was withdrawn to
synchronize the cell cycle, cells were evaluated for proliferation in
the presence of different concentrations of clotrimazole (0–
100 mM) and 10 mM 5-bromo-29-deoxyuridine (BrdU). BrdU
incorporation was analyzed after 24 h of incubation using a
europium-based time-resolved fluorescence (TRF) cell prolifera-
tion assay according to the manufacturer’s instruction (PerkinEl-
mer). Cells incubated without BrdU served as the negative control.
The mean fluorescence for each group was determined after
subtracting the mean value of the negative control from each cell.
Statistical analyses
Statistical analysis and non-linear regression was performed
using SigmaPlot 10.0 software integrated with SigmaStat 3.1
package (Systat, CA, USA). Student’s t-test was used unless
otherwise indicated. p values#0.05 were considered statistically
significant.
Author Contributions
Conceived and designed the experiments: CMF MCM MSP MLSS PZ.
Performed the experiments: CMF MCM MSP MLSS PZ. Analyzed the
data: CMF MCM MSP MLSS PZ. Contributed reagents/materials/
analysis tools: MSP PZ. Wrote the paper: MSP PZ.
References
1. Marin-Hernandez A, Rodriguez-Enriquez S, Vital-Gonzalez PA, Flores-
Rodriguez FL, Macias-Silva M, et al. (2006) Determining and understanding
the control of glycolysis in fast-growth tumor cells. Flux control by an over-
expressed but strongly product-inhibited hexokinase. FEBS J 273: 1975–1988.
2. Meadows AL, Kong B, Berdichevsky M, Roy S, Rosiva R, et al. (2008)
Metabolic and morphological differences between rapidly proliferating cancer-
ous and normal breast epithelial cells. Biotechnol Prog 24: 334–341.
3. Hsu PP, Sabatini DM (2008) Cancer Cell Metabolism: Warburg and Beyond.
Cell 134: 703–707.
4. Gillies RJ, Robey I, Gatenby RA (2008) Causes and consequences of increased
glucose metabolism of cancers. J Nucl Med 49 Suppl 2: 24S–42S.
5. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the
Warburg effect: the metabolic requirements of cell proliferation. Science 324:
1029–1033.
6. Almeida A, Bolanos JP, Moncada S (2010) E3 ubiquitin ligase APC/C-Cdh1
accounts for the Warburg effect by linking glycolysis to cell proliferation. Proc
Natl Acad Sci U S A 107: 738–741.
7. Lee HC, Wei YH (2009) Mitochondrial DNA instability and metabolic shift in
human cancers. Int J Mol Sci 10: 674–701.
8. Khalid MH, Tokunaga Y, Caputy AJ, Walters E (2005) Inhibition of tumor
growth and prolonged survival of rats with intracranial gliomas following
administration of clotrimazole. J Neurosurg 103: 79–86.
9. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, et al. (2004)
Hexokinase-mitochondria interaction mediated by Akt is required to inhibit
apoptosis in the presence or absence of Bax and Bak. Mol Cell 16: 819–830.
10. Glass-Marmor L, Beitner R (1997) Detachment of glycolytic enzymes from
cytoskeleton of melanoma cells induced by calmodulin antagonists. EurJPhar-
macol 328: 241–248.
11. Penso J, Beitner R (2002) Detachment of glycolytic enzymes from cytoskeleton of
Lewis lung carcinoma and colon adenocarcinoma cells induced by clotrimazole
and its correlation to cell viability and morphology. MolGenetMetab 76:
181–188.
12. Meira DD, Marinho-Carvalho MM, Teixeira CA, Veiga VF, Da Poian AT, et
al. (2005) Clotrimazole decreases human breast cancer cells viability through
alterations in cytoskeleton-associated glycolytic enzymes. MolGenetMetab 84:
354–362.
13. Sola-Penna M, Da Silva D, Coelho WS, Marinho-Carvalho MM, Zancan P
(2010) Regulation of mammalian muscle type 6-phosphofructo-1-kinase and its
implication for the control of the metabolism. IUBMB Life 62: 791–796.
14. Warburg O (1956) On the origin of cancer cells. Science 123: 309–314.
15. Zancan P, Sola-Penna M, Furtado CM, Da Silva D (2010) Differential
expression of phosphofructokinase-1 isoforms correlates with the glycolytic
efficiency of breast cancer cells. Mol Genet Metab 100: 372–378.
16. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL (2002) Novel
therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP
production. Cancer Res 62: 3909–3913.
17. Chen Z, Zhang H, Lu W, Huang P (2009) Role of mitochondria-associated
hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim
Biophys Acta 1787: 553–560.
18. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, et al. (2006) TIGAR, a
p53-inducible regulator of glycolysis and apoptosis. Cell 126: 107–120.
19. Penso J, Beitner R (2002) Clotrimazole decreases glycolysis and the viability of
lung carcinoma and colon adenocarcinoma cells. EurJPharmacol 451: 227–235.
20. Glass-Marmor L, Morgenstern H, Beitner R (1996) Calmodulin antagonists
decrease glucose 1,6-bisphosphate, fructose 1,6-bisphosphate, ATP and viability
of melanoma cells. EurJPharmacol 313: 265–271.
21. Shaw RJ (2006) Glucose metabolism and cancer. Current Opinion in Cell
Biology 18: 598–608.
22. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, et al. (2006) p53
regulates mitochondrial respiration. Science 312: 1650–1653.
23. Kim JW, Dang CV (2006) Cancer’s molecular sweet tooth and the Warburg
effect. Cancer Res 66: 8927–8930.
24. Tong X, Zhao F, Thompson CB (2009) The molecular determinants of de novo
nucleotide biosynthesis in cancer cells. Curr Opin Genet Dev 19: 32–37.
Clotrimazole Affects Breast Cancer Cell Metabolism
PLoS ONE | www.plosone.org 9 February 2012 | Volume 7 | Issue 2 | e3046225. Boros LG, Torday JS, Lim S, Bassilian S, Cascante M, et al. (2000)
Transforming growth factor beta2 promotes glucose carbon incorporation into
nucleic acid ribose through the nonoxidative pentose cycle in lung epithelial
carcinoma cells. Cancer Res 60: 1183–1185.
26. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, et al. (2005) ATP
citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8: 311–321.
27. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE,
et al. (2008) The M2 splice isoform of pyruvate kinase is important for cancer
metabolism and tumour growth. Nature 452: 230–233.
28. Liu YC, Li F, Handler J, Huang CR, Xiang Y, et al. (2008) Global regulation of
nucleotide biosynthetic genes by c-Myc. PLoS ONE 3: e2722.
29. Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, et al. (2008) Direct
role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma
cells. Cell Cycle 7: 2392–2400.
30. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, et al. (2004) Advanced
cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP.
Biochem Biophys Res Commun 324: 269–275.
31. Fantin VR, St-Pierre J, Leder P (2006) Attenuation of LDH-A expression
uncovers a link between glycolysis, mitochondrial physiology, and tumor
maintenance. Cancer Cell 9: 425–434.
32. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, et al. (2006) Ras
transformation requires metabolic control by 6-phosphofructo-2-kinase. Onco-
gene 25: 7225–7234.
33. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV (2007) Hypoxia-inducible
factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial
growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase
kinase 1. Mol Cell Biol 27: 7381–7393.
34. El-Bacha T, de Freitas MS, Sola-Penna M (2003) Cellular distribution of
phosphofructokinase activity and implications to metabolic regulation in human
breast cancer. MolGenetMetab 79: 294–299.
35. Tong X, Zhao F, Mancuso A, Gruber JJ, Thompson CB (2009) The glucose-
responsive transcription factor ChREBP contributes to glucose-dependent
anabolic synthesis and cell proliferation. Proc Natl Acad Sci U S A 106:
21660–21665.
36. Gatenby RA, Gillies RJ (2004) Why do cancers have high aerobic glycolysis?
NatRevCancer 4: 891–899.
37. Ouadid-Ahidouch H, Roudbaraki M, Ahidouch A, Delcourt P, Prevarskaya N
(2004) Cell-cycle-dependent expression of the large Ca2+-activated K+ channels
in breast cancer cells. Biochem Biophys Res Commun 316: 244–251.
38. Khaitan D, Sankpal UT, Weksler B, Meister EA, Romero IA, et al. (2009) Role
of KCNMA1 gene in breast cancer invasion and metastasis to brain. BMC
Cancer 9: 258.
39. Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, et al. (2002)
Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab
Dispos 30: 314–318.
40. Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, et al. (2000) Design of
a potent and selective inhibitor of the intermediate-conductance Ca2+-activated
K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A
97: 8151–8156.
41. Abdullaev IF, Rudkouskaya A, Mongin AA, Kuo YH (2010) Calcium-activated
potassium channels BK and IK1 are functionally expressed in human gliomas
but do not regulate cell proliferation. PLoS ONE 5: e12304.
42. Garland JM, Halestrap A (1997) Energy metabolism during apoptosis. Bcl-2
promotes survival in hematopoietic cells induced to apoptose by growth factor
withdrawal by stabilizing a form of metabolic arrest. JBiolChem 272:
4680–4688.
43. Gonin-Giraud S, Mathieu AL, Diocou S, Tomkowiak M, Delorme G, et al.
(2002) Decreased glycolytic metabolism contributes to but is not the inducer of
apoptosis following IL-3-starvation. Cell Death Differ 9: 1147–1157.
44. Oddis CV, Finkel MS (1995) Cytokine-stimulated nitric oxide production
inhibits mitochondrial activity in cardiac myocytes. Biochem Biophys Res
Commun 213: 1002–1009.
45. Spitz GA, Furtado CM, Sola-Penna M, Zancan P (2009) Acetylsalicylic acid and
salicylic acid decrease tumor cell viability and glucose metabolism modulating 6-
phosphofructo-1-kinase structure and activity. Biochemical Pharmacology 77:
46–53.
46. Kennelly KP, Wallace DM, Holmes TM, Hankey DJ, Grant TS, et al. (2011)
Preparation of pre-confluent retinal cells increases graft viability in vitro and in
vivo: a mouse model. PLoS ONE 6: e21365.
47. Schwartz MK, Bodansky O (1968) Utilization of automation for studies of
enzyme kinetics. Methods Biochem Anal 16: 183–218.
48. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement
with the Folin phenol reagent. Journal of Biological Chemistry 193: 265–275.
49. Coelho WS, Costa KC, Sola-Penna M (2007) Serotonin stimulates mouse
skeletal muscle 6-phosphofructo-1-kinase through tyrosine-phosphorylation of
the enzyme altering its intracellular localization. MolGenetMetab 92: 364–370.
50. Leite TC, Coelho RG, Silva DD, Coelho WS, Marinho-Carvalho MM, et al.
(2011) Lactate downregulates the glycolytic enzymes hexokinase and phospho-
fructokinase in diverse tissues from mice. FEBS Letters 585: 92–98.
51. Sola-Penna M, Meyer-Fernandes JR (1998) Stabilization against thermal
inactivation promoted by sugars on enzyme structure and function: why is
trehalose more effective than other sugars? ArchBiochemBiophys 360: 10–14.
52. Liang C-C, Park AY, Guan J-L (2007) In vitro scratch assay: a convenient and
inexpensive method for analysis of cell migration in vitro. Nature Protocols 2:
329–333.
53. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, et al. (2008) A role for TAZ in
migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 68:
2592–2598.
Clotrimazole Affects Breast Cancer Cell Metabolism
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e30462